192 related articles for article (PubMed ID: 38116291)
1. Liquid biopsy in non-small cell lung cancer: a meta-analysis of state-of-the-art and future perspectives.
Franzi S; Seresini G; Borella P; Raviele PR; Bonitta G; Croci GA; Bareggi C; Tosi D; Nosotti M; Tabano S
Front Genet; 2023; 14():1254839. PubMed ID: 38116291
[No Abstract] [Full Text] [Related]
2. Cell-Free Circulating Tumour DNA Blood Testing to Detect
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(5):1-176. PubMed ID: 32206157
[TBL] [Abstract][Full Text] [Related]
3. Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review.
Tomasik B; Skrzypski M; Bieńkowski M; Dziadziuszko R; Jassem J
Transl Lung Cancer Res; 2023 Mar; 12(3):594-614. PubMed ID: 37057121
[TBL] [Abstract][Full Text] [Related]
4. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
5. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
[TBL] [Abstract][Full Text] [Related]
6. Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer.
Veldore VH; Choughule A; Routhu T; Mandloi N; Noronha V; Joshi A; Dutt A; Gupta R; Vedam R; Prabhash K
Lung Cancer (Auckl); 2018; 9():1-11. PubMed ID: 29379323
[TBL] [Abstract][Full Text] [Related]
7. The Diagnostic Accuracy of Liquid Biopsy in EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis of 40 Studies.
Wang N; Zhang X; Wang F; Zhang M; Sun B; Yin W; Deng S; Wan Y; Lu W
SLAS Technol; 2021 Feb; 26(1):42-54. PubMed ID: 32659150
[TBL] [Abstract][Full Text] [Related]
8. Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer.
Shen H; Jin Y; Zhao H; Wu M; Zhang K; Wei Z; Wang X; Wang Z; Li Y; Yang F; Wang J; Chen K
BMC Med; 2022 Dec; 20(1):480. PubMed ID: 36514063
[TBL] [Abstract][Full Text] [Related]
9. Real-World Data of the Correlation between EGFR Determination by Liquid Biopsy in Non-squamous Non-small Cell Lung Cancer (NSCLC) and the EGFR Profile in Tumor Biopsy.
Soria-Comes T; Palomar-Abril V; Ureste MM; Guerola MT; Maiques ICM
Pathol Oncol Res; 2020 Apr; 26(2):845-851. PubMed ID: 30847713
[TBL] [Abstract][Full Text] [Related]
10. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
[TBL] [Abstract][Full Text] [Related]
11. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
Li Y; Zhang FS; Guo L; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
[No Abstract] [Full Text] [Related]
12. [Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics].
Haupts A; Roth W; Hartmann N
Pathologe; 2019 Dec; 40(Suppl 3):244-251. PubMed ID: 31797045
[TBL] [Abstract][Full Text] [Related]
13. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
[TBL] [Abstract][Full Text] [Related]
15. Epidermal Growth Factor Receptor T790M Mutation Testing in Non-Small Cell Lung Cancer: An International Collaborative Study to Assess Molecular EGFR T790M Testing in Liquid Biopsy.
Filipits M; Kainz V; Sebek V; Zach H; On Behalf Of The Liquid Biopsy Collaborative Study Group
Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444638
[TBL] [Abstract][Full Text] [Related]
16. Future Perspectives in Detecting
Ferreira D; Miranda J; Martins-Lopes P; Adega F; Chaves R
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33916986
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of liquid biopsy-based companion diagnostics in the non-small-cell lung cancer treatment.
Sato Y
Explor Target Antitumor Ther; 2022; 3(5):630-642. PubMed ID: 36338524
[TBL] [Abstract][Full Text] [Related]
18. Utility of Liquid Biopsy by Improved PNA-LNA PCR Clamp Method for Detecting EGFR Mutation at Initial Diagnosis of Non-Small-Cell Lung Cancer: Observational Study of 190 Consecutive Cases in Clinical Practice.
Ito K; Suzuki Y; Saiki H; Sakaguchi T; Hayashi K; Nishii Y; Watanabe F; Hataji O
Clin Lung Cancer; 2018 Mar; 19(2):181-190. PubMed ID: 29174086
[TBL] [Abstract][Full Text] [Related]
19. Detection of epidermal growth factor receptor mutations in peripheral blood circulating tumor DNA in patients with advanced non-small cell lung cancer: A PRISMA-compliant meta-analysis and systematic review.
Zhou S; Huang R; Cao Y
Medicine (Baltimore); 2020 Oct; 99(40):e21965. PubMed ID: 33019389
[TBL] [Abstract][Full Text] [Related]
20. Circulating DNA in
Singh AP; Li S; Cheng H
Ann Transl Med; 2017 Sep; 5(18):379. PubMed ID: 29057239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
